S&P 500
3,345.82-3.34(-0.10%)Nasdaq
11,098.43-9.64(-0.09%)Russell 2000
1,550.20+5.58(+0.36%)
IMV Inc. (IMV)
Chart Events
Performance Outlook
| Previous Close | 5.07 |
| Open | 5.05 |
| Bid | 5.04 x 1400 |
| Ask | 5.05 x 900 |
| Day's Range | 4.95 - 5.09 |
| 52 Week Range | 1.35 - 6.82 |
| Volume | 152,430 |
| Avg. Volume | 1,831,848 |
| Market Cap | 315.374M |
| Beta (5Y Monthly) | 2.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.34 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
IMV INC (IMV) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
IMV INC (IMV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- ACCESSWIRE
LD Micro - Announces Preliminary List of Presenters for the LD 500
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
- Business Wire
IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that Canadian government agencies will contribute up to CA$4.75 million to advance Phase 1 clinical development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel coronavirus SARS-COV-2.
